Anti-CD20 Monoclonal Antibodies Market to Record 7.6% CAGR Growth Through 2029 | Global Analysis Report

Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.

Anti-CD20 Monoclonal Antibodies Market Outlook: How is the Market Expected to Grow by 2025?
The market for anti-CD20 monoclonal antibodies has experienced substantial growth recently. Its size is projected to increase from $8.33 billion in 2024 to $9.00 billion in 2025, representing a compound annual growth rate (CAGR) of 7.9%. The growth seen historically can be linked to the rising occurrence of B-cell malignancies, wider uptake in treating autoimmune diseases, more FDA and EMA approvals for novel anti-CD20 therapies, and the expanding global elderly population.

Anti-CD20 Monoclonal Antibodies Market Forecast: What Size Will It Reach By 2029?
The market for anti-CD20 monoclonal antibodies is set to witness substantial expansion in the coming years, soaring to a value of $12.05 billion by 2029 at a compound annual growth rate (CAGR) of 7.6%. This anticipated growth over the forecast duration can be accredited to factors such as increasing strategic partnerships and licensing contracts, the widened use in combined treatment plans, the escalating numbers of relapsed or refractory cases, growing healthcare spending and accessibility in emerging markets, and the rise in biosimilar development and approvals. The forecast period will also see key trends such as the evolution in monoclonal antibody engineering, the incorporation of anti-CD20 antibodies in combination treatments, the advancement of technology-led personalized cancer treatments, progress in subcutaneous and prolonged-release formulations, and improvements in bispecific and cutting-edge antibodies.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report

Which Key Market Drivers Will Shape Anti-CD20 Monoclonal Antibodies Industry Trends in 2025-2029?
The anti-CD20 monoclonal antibodies market is predicted to expand due to the increasing prevalence of autoimmune diseases. These disorders arise when the immune system mistakenly targets the body's cells as harmful and attacks them. Increased exposure to environmental pollutants, which can disrupt immune regulation and initiate attacks on the body's tissues, is leading to a rise in autoimmune diseases. Anti-CD20 monoclonal antibodies alleviate symptoms of autoimmune diseases by eradicating B cells that assist in producing autoantibodies and inflammation. These antibodies help in controlling the immune response and diminishing disease symptoms. For instance, the Australian Institute of Health and Welfare, a government organization based in Australia, reported in June 2024 that about 514,000 individuals (2.0%) were living with rheumatoid arthritis, a systemic autoimmune disorder, in Australia in 2022, with 2.5% females and 1.6% males affected. Consequently, the rising incidences of autoimmune diseases are fueling the growth of the anti-CD20 monoclonal antibodies market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp

What Are the High-Growth Segments in the Anti-CD20 Monoclonal Antibodies Market?
The anti-cd20 monoclonal antibodies market covered in this report is segmented -

1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types
2) By Route Of Administration: Intravenous, Subcutaneous
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications
5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users

Subsegments:
1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux
2) By Obinutuzumab: Gazyva, Biosimilar Candidates
3) By Ofatumumab: Arzerra, Kesimpta
4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab

Which Global Trends Are Driving Anti-CD20 Monoclonal Antibodies Market Expansion?
Key players in the anti-CD20 monoclonal antibody market are directing their efforts towards developing superior products like obinutuzumab to more effectively target stubborn or recurrent B-cell malignancies. Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is specifically designed to identify and eliminate CD20-positive B cells that play a role in certain blood cancers and autoimmune disorders. Case in point, in March 2025, the US Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) from Roche, a biopharmaceutical industry leader based in Switzerland, for lupus nephritis treatment. This approval was fueled by positive outcomes from the Phase III REGENCY trial which demonstrated enhanced complete renal response (CRR) when administered in tandem with standard treatment compared to the standard treatment alone. This places Gazyva/Gazyvaro in a unique position, being the sole anti-CD20 monoclonal antibody demonstrated to offer such advantage in treating lupus nephritis, a serious inflammatory condition triggered by lupus potentially leading to kidney failure.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25693&type=smp

Who Are the Fastest-Growing Companies in the Anti-CD20 Monoclonal Antibodies Industry?
Major companies operating in the anti-cd20 monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Chugai Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories, Genmab A/S, Celltrion Inc., Innovent Biologics, Immunomedics, HLL Lifecare Limited, Shanghai Henlius Biotech Inc., TG Therapeutics, Biogen Idec, Aetos Pharma, Nycomed GmbH

What Is the Regional Outlook for the Anti-CD20 Monoclonal Antibodies Market by 2029?
North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

#Reach Out to Us#

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.